Preclinical development of novel small molecule malaria drugs that overcome drug

描述（由申请人提供）：疟疾造成的全球性健康问题由于抗药性寄生虫的传播而变得更加困难。我们已经开发了一种口服的廉价新药，可以对抗氯喹耐药性和氯喹敏感性疟疾。该项目进行了一种候选药物的临床前开发，该候选药物是从这类旨在克服耐药性的创新性强效抗疟药中选出的。候选人将通过临床前测试的最终阶段。因此，将在大鼠和猴中进行药代动力学、药效学、药理学和毒性评价。总体目标将是完成临床前研究，从而批准用于1期人体临床试验的药物的研究性新药（IND）申请。

DESCRIPTION (provided by applicant): The worldwide health problem created by malaria has been made more difficult by the spread of drug- resistant parasites. We have developed an orally available and inexpensive class of novel drugs that act against both chloroquine-resistant and chloroquine-sensitive malaria. This project carries on preclinical development of a drug candidate that has been selected from this innovative class of potent antimalarials designed to overcome drug resistance. The candidate will be advanced through the ultimate stages of preclinical testing. Thus, pharmacokinetics, pharmacodynamics, pharmacology, and toxicity evaluations will be performed in both rats and monkeys. The overall goal will be completion of preclinical studies leading to approval of an Investigative New Drug (IND) application for the drug to be used in a Phase 1 human clinical trial.